Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

OU Awarded $17 Million NIH Grant to Improve Cancer Outcomes Among Native Americans

The National Institutes of Health has awarded the University of Oklahoma a five-year, $17.2 million grant to partner with tribal nations and communities to improve cancer outcomes. Research has shown that the American Indian and Alaska Native population in Oklahoma experiences a 36% higher incidence of cancer and a 73% higher death rate from cancer than faced by the U.S. general population.

OCTSI Director elected to National Academy of Medicine

Judith A. James, M.D., Ph.D., associate vice provost for clinical and translational science and professor of medicine at the University of Oklahoma Health Campus, has been elected to the National Academy of Medicine for her work in the field of autoimmunity and autoimmune disorders.

She is the first woman from an Oklahoma institution – and fifth overall Oklahoma-based scientist – to be selected for this prestigious honor, which is widely considered one of the highest honors in the fields of health and medicine.

BERD Short Course on Biases in Diagnostic and Prognostic Research

https://osctr.ouhsc.edu/short-course

This seminar/workshop will provide a brief overview of study designs for and common biases affecting diagnostic test accuracy and prognostic studies.  Numerical examples  will be used to illustrate the impact of common biases.

3/31/2023 Noon - 1:30 pm (CDT)

Hudson College of Public Health Auditorium (CHB 150)

Lunch Provided for first 25 in-person participants

Registration Link

Subscribe to News

Recent Publications

The "M" Word: Defining Malignancy in Surgical Residencies

J Surg Educ. 2025 Nov;82(11):103660. doi: 10.1016/j.jsurg.2025.103660. Epub 2025 Sep 25.

ABSTRACT

OBJECTIVE: We sought to define the term "malignancy" in the setting of medical students applying to general surgery residencies.

DESIGN: This was a retrospective qualitative analysis of Reddit.com's yearly General Surgery Match Application spreadsheets. Programs were marked as malignant (Y), nonmalignant (N), and Mixed (Y/N). A code book was developed and responses coded. Thematic and pattern analysis was performed.

A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis Rheumatol. 2025 Sep 16. doi: 10.1002/art.43391. Online ahead of print.

ABSTRACT

OBJECTIVE: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.

Upcoming Events

Media